Skip to content
ESPT
MARKETS / NASDAQ / Health care / Pharmaceuticals / BDRX
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Biodexa Pharmaceuticals PLC BDRX

11 fiscal years on record · GBP · FY2025 reported · SEC filings only
£-6.4M
£-5.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The Phase 3 study of eRapa in FAP is a double-blind placebo-controlled trial in 168 patients, randomized 2:1 drug / placebo, conducted in approximately 30 clinical sites across the United States and Europe. On February 4, 2026 we licensed MTX240, formerly known as OPB-171775, from Otsuka Pharmaceutical Co., Ltd, or Otsuka. MTX240 acts as a molecular glue, bringing two intracellular proteins, PDE3a and SLFN12, specifically co-expressed by GIST cancer cells, into close proximity to form a stable complex.

Written from the business description in Biodexa Pharmaceuticals Plc's annual report to the U.S. Securities and Exchange Commission, filed 27 March 2026. Every sentence was checked against that document before publication.

Growth

·
Revenue, FY2025 · full 11-year series below
Revenue £M Net income £M
FY2023 · Revenue 0.4 · Net income -7.1
-10M-20M
20152018202120242025
Compound annual growth
+3.6%
−27.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −27.8% a year over the five years to FY2023.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2023 · Operating -2103.4% · Net ·
-2000%-4000%-6000%
201520202025
ROE
FY2025 · ROE -64.7%
-50%-100%-150%
201520202025
Three returns, three denominators.
Gross margin·
Operating margin·
Net margin·
EBITDA·

Each GBP of equity lost 65 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow £M
FY2025 · FCF -5.6
-10M-20M
201520202025
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsGBP 18.2M
CashGBP 8.5M
Gross debtGBP 61,000.00
Net debtGBP -8.5M
Current ratio2.03×

Net debt stands at -74% of equity.

The 11-year record

11 fiscal years
Every figure from documents filed with the SEC · GBP

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
BDRX, 11-year financial record
Metric 20252024202320222021202020192018201720162015
Revenue £B◌◌0.00.00.00.00.00.00.00.00.0
Operating income £B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA £B◌◌◌◌◌◌◌◌◌◌◌
Income tax £B−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0
Net income £B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow £B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted £−0.00−0.00−0.02−1.55◌◌◌◌◌◌◌
Dividend / sh £◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————
ROE %−64.7−88.1−180.6−112.5−63.6−168.9−55.3−58.3−40.0−43.5−21.5
Shares out B◌◌◌◌6.747.05◌◌◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 40 reconciliationsAUDITED

Reconciled in 11 of the 11 fiscal years we could check. 16 checks were skipped: the balance sheet is not tagged before 2015. 15 checks were skipped: EPS is not tagged before 2022. Eight checks were skipped: revenue is not tagged before 2015.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code X0
Fiscal year endsDecember 31
Data on record since2015

Share this section

Download image